RxDoctor Payments Data

Ankhnu Uaskhem, MD

Family Medicine · Brooklyn, NYNPI 1982797197

Payments from drug & device makers

$2,786in general payments, 2019–2025

Across 144 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$472
  • Merck$388
  • Johnson & Johnson$352
  • AstraZeneca$325
  • Novo Nordisk$286
  • Lilly USA, LLC$176
  • plus $788 from 16 others

What the payments were for

  • Food & beverage$2,74198%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,786 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$28,762
Medicare patients
80
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide542$516,193
JardianceEmpagliflozin301$198,251
FarxigaDapagliflozin Propanediol311$175,618
TrulicityDulaglutide171$174,995
EliquisApixaban193$125,768
XareltoRivaroxaban169$114,280
Trelegy ElliptaFluticasone/Umeclidin/Vilanter153$93,570
EntrestoSacubitril/Valsartan106$93,557
JanuviaSitagliptin Phosphate100$85,434
TradjentaLinagliptin145$83,671
MounjaroTirzepatide73$79,572
Breztri AerosphereBudesonide/Glycopyr/Formoterol123$76,783
OtezlaApremilast13$59,590
RybelsusSemaglutide43$47,178
JulucaDolutegravir/Rilpivirine12$38,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$286$563,371585 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$34$313,918499 claims
Lilly USA, LLCTrulicity, Mounjaro$176$254,567244 claims
AstraZenecaFarxiga, Breztri Aerosphere$325$252,400434 claims
PfizerEliquis$127$125,768193 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$60$117,967214 claims
Johnson & JohnsonXarelto$352$114,280169 claims
NovartisEntresto$472$93,557106 claims
MerckJanuvia$388$85,434100 claims
AmgenOtezla, Corlanor$37$67,95728 claims
BayerKerendia$103$16,04826 claims
Astellas Pharma US IncMyrbetriq$50$10,60215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →